Oncopeptides SPiKE Platform: Affibody-Derived NK-Cell Engager Preclinical Data for Multiple Myeloma at AACR 2026
Oncopeptides AB (Nasdaq Stockholm: ONCO) will present preclinical data on its SPiKE platform at AACR 2026, showing synergistic effects when combining an affibody-derived bispecific engager with expanded adaptive NK cells (ADAPT-NK) in a humanized multiple myeloma mouse model. The approach leverages peptide-scaffold targeting to direct NK-cell cytotoxicity at malignant plasma cells in difficult-to-treat cancers.